nach oben

Erschienen in:

01.12.2010 | Research

Tumor markers as a diagnostic key for hilar cholangiocarcinoma

verfasst von: B Juntermanns, S Radunz, M Heuer, S Hertel, H Reis, JP Neuhaus, S Vernadakis, T Trarbach, A Paul, GM Kaiser

Erschienen in: European Journal of Medical Research | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

Hilar cholangiocarcinoma is the fourth most common gastrointestinal malignancy. CA19-9 and CEA are helpful devices in the management of gastrointestinal malignancies and belong to clinical routine in surgical oncology. But the validity of these parameters in terms of tumor extension and prognosis of bile duct malignancies still remains unclear.

Methods

From 1998 to 2008, we obtained preoperative CA19-9 and CEA serum levels in 136 patients with hilar cholangiocarcinoma. We correlated tumor stage, resectability rate and survival with preoperative CA 19-9 and CEA serum levels.

Results

CA19-9 (UICC I: 253 ± 561 U/ml; UICC II: 742 ± 1572 U/ml; UICC III: 906 ± 1708 U/ml; UICC IV: 1707 ± 3053 U/ml) and CEA levels (UICC I: 2.9 ± 3.8 U/ml; UICC II: 4.6 ± 6.5 U/ml; UICC III: 18.1 ± 29.6 U/ml; UICC IV: 22.7 ± 53.9 U/ml) increase significantly with rising tumor stage. Patients with pre operative serum levels of CA19-9 (> 1000 U/ml) and CEA (> 14.4 ng/ml) showed a significant poorer resectability rate and survival than patients with lower CA19-9 and CEA serum levels respectively.

Conclusion

CA19-9 and CEA serum levels are associated with the tumor stage. If preoperatively obtained CA19-9 and CEA serum levels are highly elevated patients have an even worse survival and the frequency of irresectability is significantly higher.

Klatskin G: Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. Am J Med 1965, 38: 241–56. 10.1016/0002-9343(65)90178-6PubMedCrossRef

Bismuth H, Corlette MB: Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975,140(2):170–8.PubMed

Lang H, Kaiser GM, Zöpf T, Sotiropoulos GC, Frilling A, Malagó M, Broelsch CE: Surgical treatment of hilar cholangiocarcinoma. Chirurg 2006,77(4):325–34. 10.1007/s00104-006-1177-4PubMedCrossRef

Janargin WR, Shoup M: Surgical management of cholangiocarcinoma. Semin Liver Dis 2004,24(2):189–99. 10.1055/s-2004-828895CrossRef

Lygidakis NJ, Sgourakis GJ, Dedemadi GV, Vlachos L, Safioleas M: Long-term results following resectional sur gery for Klatskin tumors. A twenty-year personal experience. Hepatogastroenterology 2001,48(37):95–101.PubMed

Lazaridis KN, Gores GJ: Cholangiocarcinoma. Gastroenterology 2005,129(1):400.CrossRef

Li J, Kuehl H, Grabellus F, Müller SP, Radunz S, Antoch G, Nadalin S, Broelsch CE, Gerken G, Paul A, Kaiser GM: Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. J Surg Oncol 2008,98(6):438–43. 10.1002/jso.21136PubMedCrossRef

Juntermanns B, Kaiser GM, Reis H, Saner FH, Radunz S, Vernadakis S, Heuer M, Kuehl H, Paul A, Treckmann J: Klatskin-mimicking lesions of the biliary tree: Still a diagnostical and therapeutical dilemma? Hepatogastroenterology 2010, in press.

Uhlmann D, Wiedmann M, Schmidt F, Kluge R, Tannapfel A, Berr F, Hauss J, Witzigmann H: Management and outcome in patients with Klastkin-mimicking lesions of the biliary tree. J Gastrointest Surg 2006,10(8):1144–50. 10.1016/j.gassur.2006.04.003PubMedCrossRef

10.

Knoefel WT, Prenzel KL, Peiper M, Hosch SB, Gundlach M, Eisenberger CF, Strate T, Scheunemann P, Rogiers X, Izbicki JR: Klatskin tumors and Klatskin mimicking lesions of the biliary tree. EJSO 2003,29(8):658–61.PubMedCrossRef

11.

Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P: The clinical value of serum CEA, CA19–9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005,31(2):164–9. 10.1016/j.ejso.2004.09.007PubMedCrossRef

12.

Gores GJ: Early detection and treatment of cholangiocarcinoma. Liver Transpl 2000,6(6 Suppl 2):S30–4. ReviewPubMedCrossRef

13.

Laulu S, Roberts W: Performance characteristics of five automated CA19.9 assays. Am J Clin Pathol 2007,127(3):436–40. 10.1309/H52VET3M6P7GYWG1CrossRef

14.

Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jørgensen J, Wolf H, Orntoft TF: Reference values and biological variation for tumor marker CA19–9 in serum for different lewis and secretor genotypes and evaluation of secretor and lewis genotyping in a Caucasian population. Clin Chem 1999,45(1):54–61.PubMed

15.

Steinberg W: The clinical utility of the CA19–9 tumorassociated antigen. Am J Gastroenterol 1990,85(4):350–5.PubMed

16.

Robertson A, Davidson B: Mirizzi syndrome complicating an anomalous biliary tract: a novel cause of a hugely elevated CA19.9. Eur J Gastroenterol Hepatol 2007,19(2):167–9. 10.1097/MEG.0b013e3280122879PubMedCrossRef

17.

Toomey DP, Swan N, Torreggiani W, Conlon KC: Autoimmune pancreatitis: medical and surgical management. JOP 2007,8(3):335–43.PubMed

18.

Murray M, Burton F, Bisceglie A: Markedly elevated serum CA19.9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis. J Clin Gastroenterol 2007,41(1):115–7. 10.1097/MCG.0b013e31802dd094PubMedCrossRef

19.

Uygur-Bayramicli O, Dabak R, Orbay E, Dolapcioglu C, Sargin M, Kilicoglu G, Guleryuzlu Y, Mayadagli A: Type 2 diabetes mellitus and CA19.9 levels. World J Gastroenterol 2007,13(40):5357–9.PubMedCentralPubMedCrossRef

20.

Hammarström S: The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin cancer biol 1999,9(2):67–81. 10.1006/scbi.1998.0119PubMedCrossRef

21.

Wolter C, Neumeier D: Tumormarker in gastrointestinal diseases. Edited by: Siewert JR, Rothmund M, Schumpelick V. "Praxis der Viszeralchirurgie." Berlin-Heidelberg: Springer; 2006:141–154.

22.

Ito F, Cho CS, Rikkers LF, Weber SM: Hilar cholangiocarcinoma: current management. Ann Surg 2009,250(2):210–8. Review 10.1097/SLA.0b013e3181afe0abPubMedCrossRef

23.

Lygidakis NJ, Singh G, Bardaxoglou E, Dedemadi G, Sgourakis G, Nestoriois J, Malliotakis A, Pedonomou M, Safioleas M, Solomou EK, Grigorakos L, Vrachnos P: Changing trends in the management of Klatskin tumor. Hepatogastroenterology 2004,51(57):689–96.PubMed

24.

Rea DJ, Rosen CB, Nagorney DM, Heimbach JK, Gores GJ: Transplantation for cholangiocarcinoma: when and for whom? Surg Oncol Clin N Am 2009,18(2):32537. ix. Review.CrossRef

25.

Kaiser GM, Sotiropoulos GC, Jauch KW, Löhe F, Hirner A, Kalff JC, Königsrainer A, Steurer W, Senninger N, Brockmann JG, Schlitt HJ, Zülke C, Büchler MW, Schemmer P, Settmacher U, Hauss J, Lippert H, Hopt UT, Otto G, Heiss MM, Bechstein WO, Timm S, Klar E, Hölscher AH, Rogiers X, Stangl M, Hohenberger W, Müller V, Molmenti EP, Fouzas I, Erhard J, Malagó M, Paul A, Broelsch CE, Lang H: Liver transplantation for hilar cholangiocarcinoma: a german survey. Transplant Proc 2008,40(9):3191–3. 10.1016/j.transproceed.2008.08.039PubMedCrossRef

26.

Lang H, Sotiropoulos GC, Kaiser GM, Molmenti EP, Malagó M, Broelsch CE: The role of liver transplantation in the treatment of hilar cholangiocarcinoma. HPB (Oxford) 2005,7(4):268–72. 10.1080/13651820500372780CrossRef

27.

Kaiser GM, Oldhafer KJ, Zhang HW, Frühauf NR, Müller AB, Sauerwein W, Stuschke M, Broelsch CE: Treatment of nonresectable proximal bile duct carcinoma using intraoperative radiotherapy combined with hepatojejunostomy. J Surg Oncol 2002,81(1):55–7. 10.1002/jso.10130PubMedCrossRef

28.

Kaiser GM, Frühauf NR, Lang H, Sauerwein W, Sotiropoulos GC, Zöpf T, Grabellus F, Wittig A, Oldhafer KJ, Malagó M, Broelsch CE: Impact of intraoperative radiotherapy (IORT) on survival of patients with unresectable hilar cholangiocarcinoma. Hepatogastroenterology 2008,55(88):1951–4.PubMed

29.

Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, Otsuka M, Fukao K: Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 2000,46(3):581–7. 10.1016/S0360-3016(99)00472-1PubMedCrossRef

30.

Nishio H, Nagino M, Oda K, Ebata T, Arai T, Nimura Y: TNM classification for perihilar cholangiocarcinoma: comparison between 5th and 6th editions of the AJCC/UICC staging system. Langenbecks Arch Surg 2005,390(4):319–27. Epub 2005 Jul 7 10.1007/s00423-005-0561-8PubMedCrossRef

Titel: Tumor markers as a diagnostic key for hilar cholangiocarcinoma
verfasst von: B Juntermanns
S Radunz
M Heuer
S Hertel
H Reis
JP Neuhaus
S Vernadakis
T Trarbach
A Paul
GM Kaiser
Publikationsdatum: 01.12.2010
Verlag: BioMed Central
Erschienen in: European Journal of Medical Research / Ausgabe 8/2010
Elektronische ISSN: 2047-783X
DOI: https://doi.org/10.1186/2047-783X-15-8-357

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2010

What harm does a second delivery to the pelvic floor?

Liver volume measurement: reason of the difference between in vivo CT-volumetry and intraoperative ex vivo determination and how to cope it

Extranodal diffuse non hodgkin lymphoma in the thigh

In vitro chemosensitivity of head and neck cancer cell lines

Different surgical strategies for chronic pancreatitis significantly improve long-term outcome: a comparative single center study